Should We Rewrite the Human Genome?
By Alex Harding,
Xconomy
| 11. 28. 2016
Scientists are engineering a new living thing: a radically modified version of the lowly bacterium E. coli. In an article in Science from August, researchers at Harvard University described an ongoing project to build the genetic code of E. coli from scratch, but with major revisions to create a new strain unlike any in existence.
The modified E. coli is meant to be so foreign to viruses that they will not be able to infect it. George Church, the principal investigator on the study, told me the finished product “will be completely, unassailably resistant to all viruses, even viruses never seen before.” This offers important advantages in industrial processes such as pharmaceutical and biofuel manufacturing, said Matthieu Landon, one of the lead authors on the paper. (Genzyme, a biotechnology company, suffered a crippling viral contamination in 2009 at its Allston, MA, plant that made two essential drugs unavailable for the patients who depended upon them. A virus-resistant cell would not be vulnerable to such contamination.)
The E. coli project is a step toward the synthesis of a human genome...
Related Articles
Since the “CRISPR babies” scandal in 2018, no additional genetically modified babies are known to have been born. Now several techno-enthusiastic billionaires are setting up privately funded companies to genetically edit human embryos, with the explicit intention of creating genetically modified children.
Heritable genome editing remains prohibited by policies in the overwhelming majority of countries that have any relevant policy, and by a binding European treaty. Support for keeping it legally off limits is widespread, including among scientists...
By Ed Cara, Gizmodo | 06.22.2025
In late May, several scientific organizations, including the International Society for Cell and Gene Therapy (ISCT), banded together to call for a 10-year moratorium on using CRISPR and related technologies to pursue human heritable germline editing. The declaration also outlined...
By Isabel van Brugen, Newsweek | 06.05.2025
A U.S.-based biotech company has unveiled a new in vitro fertilization (IVF) option that allows parents to select embryos based on genetic markers tied to health and longevity.
DNA testing and analysis company Nucleus Genomics has announced the world's first...
By Jonathan D. Grinstein, PhD, Inside Precision Medicine | 06.03.2025
On Tuesday, 307 days after he was first admitted to Children’s Hospital of Philadelphia (CHOP), KJ Muldoon went home after being successfully treated with the first personalized CRISPR gene editing therapy. KJ, who was born with a serious and...